| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6617317 | TAKEDA PHARMS USA | Boronic ester and acid compositions |
Oct, 2014
(9 years ago) | |
| US5780454 | TAKEDA PHARMS USA | Boronic ester and acid compounds |
May, 2017
(6 years ago) | |
| US6713446 | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jan, 2022
(2 years ago) | |
| US6958319 | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jan, 2022
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6083903 | TAKEDA PHARMS USA | Boronic ester and acid compounds, synthesis and uses |
Oct, 2014
(9 years ago) | |
| US7119080 | TAKEDA PHARMS USA | Boronic ester and acid compounds, synthesis and uses |
Oct, 2014
(9 years ago) | |
| US6747150 | TAKEDA PHARMS USA | Boronic ester and acid compounds, synthesis and uses |
Oct, 2014
(9 years ago) | |
| US6297217 | TAKEDA PHARMS USA | Boronic ester and acid compounds, synthesis and uses |
Oct, 2014
(9 years ago) | |
|
US5780454 (Pediatric) | TAKEDA PHARMS USA | Boronic ester and acid compounds |
Nov, 2017
(6 years ago) | |
|
US6713446 (Pediatric) | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jul, 2022
(1 year, 8 months ago) | |
|
US6958319 (Pediatric) | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jul, 2022
(1 year, 8 months ago) | |
Velcade is owned by Takeda Pharms Usa.
Velcade contains Bortezomib.
Velcade has a total of 11 drug patents out of which 11 drug patents have expired.
Expired drug patents of Velcade are:
- US6083903
- US7119080
- US6747150
- US6297217
- US5780454*PED
- US6713446*PED
- US6958319*PED
- US6617317
- US5780454
- US6713446
- US6958319
Velcade was authorised for market use on 13 May, 2003.
Velcade is available in injectable;intravenous, subcutaneous dosage forms.
Velcade can be used as treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy.
The generics of Velcade are possible to be released after 25 July, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 08, 2021 |
| M(M-139) | Aug 08, 2017 |
| M(M-165) | Sep 14, 2018 |
| New Indication(I-695) | Oct 08, 2017 |
| New Dosing Schedule(D-142) | Oct 08, 2017 |
| New Dosing Schedule(D-141) | Oct 08, 2017 |
| Orphan Drug Exclusivity(ODE-76) | Oct 08, 2021 |
| Pediatric Exclusivity(PED) | Apr 08, 2022 |
| NR(NR) | Jan 23, 2015 |
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 13 May, 2003
Treatment: Treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy
Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
VELCADE family patents
